Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jan 9;63(6):1160-1168.
doi: 10.1515/cclm-2024-1258. Print 2025 May 26.

Comparison between monotest and traditional batch-based ELISA assays for therapeutic drug monitoring of infliximab and adalimumab levels and anti-drug antibodies

Mikel Moneo  1 , Ainhoa Ruiz Del Agua  1 , Begoña Ruiz-Argüello  2 , Noelia Rapun  3 , Daniel Nagore  2 , Rachid El Hamss  1
Affiliations
Free article
Comparative Study

Comparison between monotest and traditional batch-based ELISA assays for therapeutic drug monitoring of infliximab and adalimumab levels and anti-drug antibodies

Mikel Moneo et al. Clin Chem Lab Med. .
Free article

Abstract

Objectives: To compare a new ready-to-use monotest immunoassay, CHORUS Promonitor, for the quantification of serum biological drug levels and anti-drug antibodies of anti-TNF agents, against the reference batch-based ELISA test, Promonitor.

Methods: Blood samples were collected from patients treated with anti-TNF agents, infliximab (IFX) or adalimumab (ADL). IFX and ADL levels, as well as anti-IFX and anti-ADL antibodies were quantified and compared between the standard ELISA reference test, Promonitor, and the automated monotest ELISA assay, CHORUS Promonitor. Data analysis included both qualitative and quantitative comparison between both tests. For the qualitative comparison, overall percent agreement (OPA) was calculated. For the quantitative comparison, Passing-Bablok regression analysis and Bland-Altman analysis were used.

Results: For IFX and ADL levels, the qualitative overall agreement between methods was 100 % (Cohen's coefficient=1). For anti-IFX and anti-ADL antibodies, OPA was 98.8 % and 97.3 %, respectively. Quantitative comparison indicated a very strong correlation between both assays: IFX (r=0.97, n=74), ADL (r=0.95, n=54), anti-IFX (r=0.93, n=72), and anti-ADL (r=0.97, n=61). The regression analysis determined an excellent comparability of drug levels between methods. Bland-Altman analysis showed a bias difference between assays of 6 % for IFX, 0 % for ADL, 24 % for anti-IFX, and 14 % for anti-ADL.

Conclusions: Monotest CHORUS Promonitor was a reliable assay to quantify IFX, ADL, anti-IFX and anti-ADL in samples with comparable results to those obtained with the reference batch-based ELISA technique.

Keywords: anti-TNF inhibitors; anti-drug antibodies; comparative study; drug levels; immunoassay; therapeutic drug monitoring.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Lis, K, Kuzawińska, O, Bałkowiec-Iskra, E. Tumor necrosis factor inhibitors – state of knowledge. Arch Med Sci 2014;10:1175–85.
    1. Roda, G, Jharap, B, Neeraj, N, Colombel, JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol 2016;7:e135. https://doi.org/10.1038/ctg.2015.63 . - DOI
    1. Baert, F, Noman, M, Vermeire, S, Van Assche, G, G, DH, Carbonez, A, et al.. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601–8. https://doi.org/10.1056/nejmoa020888 . - DOI
    1. Papamichael, K, Cheifetz, AS. Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy. Am J Gastroenterol 2017;112:673–6. https://doi.org/10.1038/ajg.2017.21 . - DOI
    1. Rosas, J, Llinares-Tello, F, de la Torre, I, Santos-Ramírez, C, Senabre-Gallego, JM, Valor, L, et al.. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. Clin Exp Rheumatol 2014;32:942–8.

Publication types

LinkOut - more resources